Pulse Biosciences (NASDAQ:PLSE) Director Robert Duggan Acquires 660,233 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) Director Robert Duggan bought 660,233 shares of the company’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the completion of the acquisition, the director directly owned 48,211,433 shares of the company’s stock, valued at approximately $949,283,115.77. This represents a 1.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE remained flat at $19.08 during midday trading on Monday. The stock had a trading volume of 953,297 shares, compared to its average volume of 318,598. Pulse Biosciences, Inc has a 1 year low of $12.56 and a 1 year high of $26.30. The stock’s 50 day moving average price is $20.85 and its 200 day moving average price is $17.59. The company has a market capitalization of $1.30 billion, a P/E ratio of -17.35 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.25 million. Equities research analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on PLSE. Oppenheimer restated an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Tuesday, April 21st. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Mizuho set a $30.00 price target on Pulse Biosciences in a research note on Friday, February 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $30.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PLSE. Tudor Investment Corp ET AL purchased a new position in Pulse Biosciences during the 4th quarter worth $382,000. Inspire Investing LLC increased its holdings in Pulse Biosciences by 33.4% during the 4th quarter. Inspire Investing LLC now owns 34,192 shares of the company’s stock worth $469,000 after purchasing an additional 8,561 shares during the period. California State Teachers Retirement System increased its holdings in Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock worth $291,000 after purchasing an additional 3,991 shares during the period. Russell Investments Group Ltd. increased its holdings in Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares during the period. Finally, ExodusPoint Capital Management LP increased its holdings in Pulse Biosciences by 14.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 25,122 shares of the company’s stock worth $345,000 after purchasing an additional 3,258 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.